Boothbay Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Boothbay Fund Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67,500	Closed	-$1.55M	–	2406
2025 Q4	$1.55M	Buy	67,500 +34,500	+105%	+$1.13M	0.02%	661
2025 Q3	$993K	Sell	33,000 -75,000	-69%	-$2.25M	0.01%	841
2025 Q2	$3.93M	Buy	108,000 +77,700	+256%	+$2.8M	0.08%	347
2025 Q1	$1.1M	Buy	+30,300	New	+$1.26M	0.03%	596
2021 Q2	–	Sell	-22	Closed	-$250K	–	2067
2021 Q1	$250K	Buy	+22	New	+$3K	0.01%	1274

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Boothbay Fund Management's RARE Position: Q2 2026 in Review

Boothbay Fund Management increased its Ultragenyx Pharmaceutical (RARE) stake by 10% in Q2 2026, buying an estimated $363K and bringing the position to 156,612 shares worth $5.23M. The position accounts for 0.07% of the portfolio, ranked #338.

Boothbay Fund Management first reported a position in RARE in Q4 2019 and has held it in 10 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Boothbay Fund Management held 156,612 shares of Ultragenyx Pharmaceutical worth $5.23M as of Q2 2026.
Boothbay Fund Management bought 14,634 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $363K.
Ultragenyx Pharmaceutical made up 0.07% of Boothbay Fund Management's portfolio in Q2 2026, its #338 holding.
Boothbay Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 10 quarters since.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.